Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Feb;104(2):e65-e67.
doi: 10.3324/haematol.2018.199844. Epub 2018 Sep 6.

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study

Paolo Strati  1 , Michelle A Fanale  2   3 , Yasuhiro Oki  2 , Francesco Turturro  2 , Luis E Fayad  2 , Nancy L Bartlett  4 , Douglas E Gladstone  5 , Yvette L Kasamon  5 , Carol S Portlock  6 , Wyndham H Wilson  7 , Andre Goy  8 , Anas Younes  6 , Hun Ju Lee  9
Affiliations
Clinical Trial

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study

Paolo Strati et al. Haematologica. 2019 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Survival of patients with advanced stage, high-risk classical Hodgkin lymphoma treated with ABVD alone or with ABVD plus rituximab. (A) Event-free survival (EFS) by treatment arm. (B) EFS by treatment arm and CD20 status. (C) Overall survival (OS) by treatment arm. ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; R-ABVD: rituximab plus doxorubicin, bleomycin, vinblastine, and dacarbazine.
See this image and copyright information in PMC

References

    1. Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International Database on Hodgkin’s Disease Overview Study Group. J Clin Oncol. 1998;16(3):818–829. - PubMed
    1. Rassidakis GZ, Medeiros LJ, Viviani S, et al. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin’s disease: associations with presenting features and clinical outcome. J Clin Oncol. 2002;20(5):1278–1287. - PubMed
    1. Kim S, Fridlender ZG, Dunn R, et al. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models. J Immunother. 2008;31(5):446–457. - PubMed
    1. Jones RJ, Lin L, Gocke C, et al. Clonotypic B cells circulate in Hodgkin’s lymphoma (HL). Blood. 2006;108(11):143a.
    1. Younes A, Romaguera J, Hagemeister F, et al. A pilot study of ritux- imab in patients with recurrent, classic Hodgkin disease. Cancer. 2003;98(2):310–314. - PubMed

MeSH terms

Supplementary concepts